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High levels of atherogenic lipids in pregnancy are associated with health complications for the mother, 
the fetus and the newborn. As endocrine secretory tissue, the human placenta releases apolipoproteins 
(apos), particularly apoA1 and apoE. However, the magnitude and the directionality of the apo 
secretions remain unknown. We aimed to 1) determine the amount and orientation (apical-maternal 
versus basal-fetal) of placentally secreted apoA1 and apoE using human perfused placenta and primary 
trophoblast cell (PTC) culture, 2) compare apoA1 and apoE secretions of PTC with that of hepatocytes 
and 3) associate the obtained results with human blood levels by determining apoA1 and apoE 
concentrations in maternal and fetal serum samples. In perfused placenta and serum samples, apoA1 
and apoE concentrations were significantly higher at the maternal compared to the fetal side. For apoE 
a similar trend was found in PTC. For apoA1, the secretion to the apical side declined over time while 
release to the basal side was stable resulting in significantly different apoA1 concentrations between 
both sides. Unexpectedly, PTC secreted significantly higher amounts of apoA1 and apoE compared 
to hepatocytes. Our data indicate that the placenta may play an important role in maternal and fetal 
cholesterol homeostasis via secretion of anti-atherogenic apos.
Fetal development and growth depend on appropriate in utero homeostasis, which is regulated by placental trans-
port and metabolism of maternal nutrients into the fetal circulation1. A dysregulation in the placental transport 
of nutrients is an important risk factor for complications during perinatal development that can extend into 
adult life2,3. In this context, cholesterol plays an important role as nutrient required for normal fetal develop-
ment. Moreover, it is an essential component of cell membranes and for the synthesis of steroid hormones4. In 
the maternal lymphatic and blood circulations cholesterol is transported in the form of lipoproteins such as 
high-density lipoprotein (HDL), low-density lipoprotein (LDL) or very low-density lipoprotein (VLDL). During 
early developmental stages, when the fetus is incapable of its own cholesterol synthesis, placental transfer of 
maternal cholesterol is critical. Placental secretory and transport functions are regulated by numerous signals 
of fetal, maternal, and placental origin. Cholesterol is taken up at the maternal (apical) side of the placental 
syncytiotrophoblast (STB) through receptor-mediated endocytosis as well as receptor independent transport 
processes5,6. The implicated receptors are expressed in the placenta and/or STB7,8. To exit the fetal (basolateral) 
side of STB, cholesterol can be complexed with apolipoproteins (apos). Besides its beneficial aspects in human 
physiology, an excess of cholesterol can also be harmful9. Several observational studies consistently show an 
association between elevated LDL cholesterol and high prevalence of cardiovascular disease in adults, and, on the 
other hand, between high HDL cholesterol and reduced prevalence of these diseases10–12. Though this concept has 
been recently debated10,13, it is a well established and still widely accepted paradigm. Interestingly, pregnancy is 
a proatherogenic-like physiological state, which is accompanied by substantial dyslipidemia in second and third 
trimester14,15. Moreover, pathologies such as preeclampsia, a human pregnancy-related disease, impair mater-
nal vascular functions and compromise fetal development. Indeed, preeclamptic mothers exhibit elevated total 
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cholesterol, LDL-cholesterol and triglycerides in the blood16–18. If or to what extent the placenta does affect the 
pregnancy-related hyperlipidemia is currently not clear.
ApoA1 is a major apo of HDL cholesterol and is involved in the regulation of reverse cholesterol transport and 
the metabolism of HDL particles19. This transport process is regulated by a physical interaction of apoA1 with its 
molecular partner, the ATP-binding cassette (ABC) transporter A1 (ABCA1), located in the plasma membrane. 
In a very recent study, Kallol et al.20 demonstrated that ABCA1 is predominantly expressed on the apical (mater-
nal) side of the placental STB. Similarly, efflux of cholesterol was detected mainly to the apical as compared to the 
basal (fetal) side of STB. Interestingly, the placental expression of ABCA1 is markedly reduced in preeclamptic 
pregnancies21.
ApoE, a major constituent of VLDL, has been shown to be an essential ligand for the uptake and clearance 
of atherogenic lipoproteins. Moreover, it has been demonstrated that apoE plays an important role in ather-
osclerosis by modifying inflammatory responses and facilitating cholesterol efflux from cells22,23. In support 
of these findings, genetic ablation of apoE was found to cause severe atherosclerosis throughout the arterial 
tree24. Additionally, it was suggested that apoE polymorphisms play an important role in the development of 
pre-eclampsia25 and apoE is crucial for fetal cholesterol metabolism26.
Studies performed in placental explants and in trophoblast cell cultures have shown that the placenta secretes 
apoB–containing lipoproteins27. Although the release of the two anti-atherogenic apos, apoA1 and apoE by the 
placenta has been reported28,29, the directionality of the secretion towards fetal, maternal or both compartments 
remains unknown. Additionally, the quantitative capacity of the placenta to synthesize, store and release apos has 
not been determined. These aspects, however, are fundamental as apos could have a major impact on the moth-
er’s lipid profile during pregnancy and could play a supportive role in regulating maternal and fetal cholesterol 
homeostasis.
Therefore, the objectives of the present study were to (1) quantitatively assess placental apoA1 and apoE secre-
tion, (2) determine the directionality (maternal versus fetal orientation) of apoA1 and apoE release by the human 
placenta, (3) compare apoA1 and apoE secretion in primary trophoblasts with that in hepatocytes and (4) analyze 
the physiological serum concentrations of apoA1 and apoE in corresponding maternal and fetal human serum 
samples. The quantity and directionality of apoA1 and apoE secretions were investigated by using two highly 
physiological models each of them offering maternal-like and fetal-like compartments: (1) the ex vivo dual per-
fusion of healthy term human placenta, and (2) an in vitro model with human trophoblast cell isolated from term 
placenta and cultured on Transwell filter supports forming a tight monolayer of STB. To quantitatively assess the 
amount of placental apo release, and thereby to determine the physiological relevance of placental apo secretion, 
we compared the secretion of apoA1 and apoE between primary trophoblasts and primary hepatocytes using 
conventional cell culture conditions. Indeed, the liver plays a key role in promoting physiological changes and 
adaptations occurring during pregnancy (for review, see30) and is one of the major organs involved in the regula-
tion of lipid and lipoprotein homeostasis31,32. In the present work, we show for the first time that the placenta has 
the bi-directional capacity to secrete apoA1 and apoE with a predominant orientation to the apical (maternal) 
side. In line with the placenta perfusion data, apoA1 and apoE concentrations measured in corresponding mater-
nal and fetal serum samples showed also significantly higher apoA1 and apoE levels in the mother. We further 
demonstrate that primary trophoblasts secrete higher levels of apoA1 and apoE compared to primary hepatocytes 
in culture. Collectively, these data indicate that the placenta plays an important role in the regulation of maternal 
and fetal cholesterol homeostasis via secretion of anti-atherogenic apos during pregnancy.
Results
Ex vivo dual perfusion model of the human placenta. Validation of the perfusion system. To deter-
mine the magnitude and the directionality of apoA1 and apoE secretion in a highly physiological system, we 
used the ex vivo dual perfusion model of the healthy human placenta. Depending on the size and area of the 
perfused cotyledon, a variable number of canulae were inserted at the maternal side. For the present experiments 
the weight of the of perfused cotyledons varied between 25.0 g and 49.6 g resulting in the insertion of 16 to 25 
canulae. (Supplemental Table S2). To demonstrate integrity and viability of the perfused placental tissue several 
parameters including the volume of the fetal perfusate, pH, consumption of oxygen and glucose and production 
of lactate were monitored (Table 1). The pH in the maternal and fetal perfusates was within the physiological 
range of 7.3 to 7.4 and remained unchanged. The pO2 ranges for maternal arterial and venous samples were 
133.0–147.7 mmHg and 76.4–109.0 mmHg, respectively (n = 4). In fetal arterial and venous samples the pO2 val-
ues ranged between 51.0–70.5 mmHg and 62.3–82.1 mmHg, respectively (n = 4). Lactate production was constant 
(0.33 ± 0.05 µmol/min/g after 60 and 240 minutes). Oxygen consumption was constant throughout perfusion 
(0.40 ± 0.10 µL/min/g after 60 and 240 minutes). Consumption of glucose showed a slight increase (0.122 ± 0.02 
Placental perfusion parameters
pH
O2 consumption 
μL/min/g
Glucose 
consumption 
μmol/min/g
Lactate 
production 
μmol/min/g
Antipyrine 
clearance ml/
min
Creatinine 
clearance ml/
min
Maternal 
artery Fetal artery
60 minutes 7.4 ± 0.06 7.3 ± 0.01 0.4 ± 0.10 0.122 ± 0.02 0.33 ± 0.05 2.1 ± 0.4 0.8 ± 0.1
240 minutes 7.4 ± 0.04 7.3 ± 0.01 0.4 ± 0.10 0.155 ± 0.02 0.33 ± 0.05 2.5 ± 0.5 0.8 ± 0.2
Table 1. Summary of placental perfusion parameters (n = 4).
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and 0.155 ± 0.122 µmol/min/g after 60 and 240 minutes, respectively). Clearance of antipyrine and creatinine 
were determined to assess matching between maternal and fetal circuit. Antipyrine clearance increased slightly 
(2.1 ± 0.4 and 2.5 ± 0.5 ml/min after 60 and 240 minutes, respectively) whereas creatinine clearance remained 
unchanged at 0.8 ± 0.1/0.2 ml/min (Table 1).
Directionality of apolipoprotein secretion during perfusion. The measurement of apoA1 and apoE in the mater-
nal and fetal perfusates revealed interesting secretion patterns. First of all, we observed that apoA1 and apoE 
were predominantly released to the maternal compartment (apoA1 ranging from 338.30 ± 41.31 ng/mL/g to 
64.45 ± 15.52 ng/mL/g and apoE ranging from 1.34 ± 0.49 ng/mL/g to 0.12 ± 0.03 ng/mL/g) in comparison 
to the fetal compartment (apoA1 between 1.34 ± 0.49 ng/mL/g and 0.13 ± 0.04 ng/mL/g and apoE between 
0.09 ± 0.01 ng/mL/g and 0.01 ± 0.001 ng/mL/g) (Figs 1 and 2A,B). To elucidate how the perfusion process alters 
the tissue content of the apos, we measured the concentrations of apoA1 and apoE in placental tissue before and 
after perfusion by ELISA. We found approximately 4-fold lower apoA1 and apoE concentrations in the placental 
tissues after four hours of perfusion as compared to adjacent non-perfused tissue (Figs 1C and 2C). During the 
course of perfusion, we noticed continuous decreases in apoA1 and apoE release towards both the maternal and 
fetal compartment (Figs 1 and 2, panels A and B). The release of apoA1 towards the maternal and fetal compart-
ments was 4- and 14-times, respectively, lower at the end compared to the beginning of the perfusion. For apoE 
the corresponding decreases were 3- and 11-fold for the maternal and fetal side, respectively. In a next step, we 
evaluated whether the decrease in apo secretion is due to deteriorating placental function over perfusion time or 
if this is a consequence of diminishing placental apo content. Thus, we related the amount of the apos secreted at 
the beginning and at the end of perfusion to their corresponding stores at the respective time points (Figs 1C and 
2C). When the data are expressed as the percentage of apo release related to the remaining availability within the 
tissue, we found that the secretion of apoA1 and apoE to the maternal compartment at the beginning and end of 
Figure 1. Secretion of apoA1 by the human perfused placenta. Four term human placentas were initially 
perfused for 30 minutes with DMEM medium and EBSS buffer containing 2 g/L of glucose, 10 g/L Dextran 
FP40, 40 g/L BSA and 2.5 IE/mL heparin. This washing phase was followed by 240 minutes perfusion of the 
maternal and fetal circulation as an open/open system. Samples were taken at 15, 30, 90, 120, 150, 180, 210 and 
240 minutes. (A,B) The concentration of apoA1 in the maternal (A) and the fetal perfusate (B) was measured 
at each time point by ELISA and normalized to the weight of the cotyledon (g). (C) Measurement of apoA1 
concentrations in placental tissue lysates before and after the perfusion by ELISA. The concentration was 
normalized to the total protein content (mg). Results represent mean ± SEM of four independent experiments 
measured in triplicates; *p < 0.05.
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perfusion remained quite constant (11.60% vs 10.30%, for apoA1 and 2.14% vs 2.80%, for apoE, respectively). In 
contrast, the secretion of apoA1 and apoE to the fetal compartment was at the beginning about three fold higher 
than at the end of the perfusion when the remaining tissue content was taken into account (0.06 vs 0.02% for 
apoA and 0.27 vs 0.10% for apoE, respectively).
In vitro primary trophoblast models. Directionality of apolipoprotein secretion in Transwell system. In 
order to validate our findings from the placenta perfusion in an additional physiological system, we investigated 
the magnitude and directionality of apoA1 and apoE secretion in primary trophoblast cells grown as monolayers 
on Transwell filter supports. Overall, the secretion of apoA1 into the cell culture medium was approximately 
10-fold lower than that of apoE (Fig. 3A and B). Although not statistically significant, the concentration of 
apoA1 showed a trend for a decrease during culturing time in the apical (maternal) chamber (0.28 ± 0.20 ng/mL, 
0.14 ± 0.07 ng/mL and −0.02 ± 0.12 ng/mL for day 1, 3 and 5, respectively; Fig. 3A). No difference was found for 
apoA1 secretion in the basal (fetal) chamber during the culturing time (0.47 ± 1.90 ng/mL, 0.76 ± 0.29 ng/mL 
and 0.54 ± 0.17 ng/mL for day 1, 3 and 5, respectively; Fig. 3A). At day five, apoA1 secretion was significantly 
higher at the basal side in comparison to the apical compartment (−0.02 ± 0.12 ng/mL vs 0.54 ± 0.17 ng/mL; 
p = 0.0207; Fig. 3A). ApoE was continually secreted to both compartments and showed no decline over 5 days of 
culturing (Fig. 3B). However, at all-time points the secretion of apoE to the apical chamber (7.66 ± 1.90 ng/mL, 
6.68 ± 1.89 ng/mL and 6.29 ± 1.80 ng/mL for day 1, 3 and 5, respectively) was significantly higher than to the basal 
chamber (1.54 ± 0.53 ng/mL, 1.67 ± 0.62 ng/mL and 1.42 ± 0.49 ng/mL for day 1, 3 and 5, respectively; Fig. 3B).
Comparison of apo secretion between primary trophoblasts and primary hepatocytes. In 
order to determine the potential physiological relevance of placental apo release, the secretory capacity of pri-
mary trophoblasts was compared to primary hepatocytes. After culturing cells on conventional plates for three 
days, apoA1 secretion was significantly higher (day 1: 8.26 ± 1.23 vs 4.81 ± 0.20 ng/mg protein; p = 0.005; day 2: 
7.63 ± 1.1 vs 4.87 ± 0.19 ng/mg protein p = 0.007) in primary trophoblast as compared to primary hepatocytes 
Figure 2. Secretion of apoE in the human perfused placenta. Four term human placentas were initially 
perfused for 30 minutes with DMEM medium and EBSS buffer containing 2 g/L of glucose, 10 g/L Dextran 
FP40, 40 g/L BSA and 2.5 IE/mL heparin. This washing phase was followed by 240 minutes perfusion of the 
maternal and fetal circulation as an open/open system. Samples were taken at 15, 30, 90, 120, 150, 180, 210 and 
240 minutes. (A,B) The concentration of apoE in the maternal (A) and the fetal perfusate (B) was measured 
at each time point by ELISA and normalized to the weight of the cotyledon (g). (C) Measurement of apoE 
concentrations in placental tissue lysates before and after the perfusion by ELISA. The concentration was 
normalized to the total protein content (mg). Results represent mean ± SEM of four independent experiments 
measured in triplicates; *p < 0.05.
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(Fig. 4A). In agreement with our previous studies using primary trophoblast on the Transwell system (Fig. 3A), 
there was again a significant decrease in the secretion of apoA1 during the culturing time (day 1: 8.26 ± 1.23 vs 
day 3: 5.165 ± 0.83 ng/mg protein; p < 0.05; Fig. 4A). No difference in apoA1 secretion was observed in primary 
hepatocytes during three days of culture (Fig. 4A).
Similarly, apoE secretion was significantly higher (day 1: 30.48 ± 2.6 vs 3.02 ± 0.22 ng/mg protein; p < 0.0001; 
day 2: 27.80 ± 2.70 vs 2.79 ± 0.21 ng/mg protein; p < 0.0001; day 3: 23.70 ± 2.70 vs 2.72 ± 0.28 ng/mg protein; 
p < 0.0001) in primary trophoblasts as compared to primary hepatocytes (Fig. 4B). The amount of secreted apoE 
did not change during the culturing time in primary hepatocytes; however, there was a significant decrease of 
apoE secretion in primary trophoblast during the culturing time (day 1: 30.48 ± 2.6 vs day 3: 23.7 ± 2.7 ng/mg 
protein; p < 0.01; Fig. 4B).
Comparison of apoA1 and apoE levels between maternal and fetal serum samples. To rein-
force our ex vivo and in vitro data and relate them to the physiological context in the blood, we measured the 
levels of apoA1 and apoE in corresponding maternal and fetal serum samples (n = 40). ApoA1 concentrations 
were approximately 6-fold higher in maternal as compared to fetal serum samples (3874.0 ± 177.8 µg/ml vs 
648.0 ± 23.2 µg/ml p < 0.0001, Fig. 5A). Similarly, a significant increase in the apoE levels was found in maternal 
as compared to the fetal serum samples (86.57 ± 4.90 µg/ml vs 60.33 ± 2.50 µg/ml p < 0.0001, Fig. 5B). However, 
Figure 3. Secretion of apoA1 and apoE by primary trophoblasts seeded on Transwell filter supports. 
Primary trophoblast cells were isolated form healthy human term placentas (n = 5) and seeded at a density 
of  1× 106 cells/cm2 on Transwell inserts. Cells were cultured for five days in DMEM containing 4.5 g/l glucose 
supplemented with 10% fetal bovine serum and antibiotic-antimycotic. Details of establishment of confluent 
human primary trophoblasts monolayer are described in the Materials and Methods section. The medium was 
collected at day one, three and five. (A,B) ELISA measurements of apoA1 (A) and apoE (B) concentrations in 
the apical and basal compartment. Results represent mean ± SEM of five independent experiments performed 
in triplicates; *p < 0.05; **p < 0.01.
Figure 4. Secretion of apoA1 and apoE by primary hepatocytes and primary trophoblasts. Primary hepatocytes 
and primary trophoblast cells were isolated from human liver of colorectal metastases patients (n = 6) and from 
healthy human term placentas (n = 6) as described in the Materials and Methods section. Primary hepatocytes 
and primary trophoblasts were seeded at a density of 75000 cells/cm2 and 0.5 × 106 cells/cm2, respectively, on 
conventional plates and cultured for three days. Each day, the medium was collected and cellular protein content 
determined. (A,B) Quantification of apoA1 (A) and apoE (B) by ELISA. The concentration was normalized to 
the respective protein concentration. Results represent mean ± SEM of six independent experiments performed 
in triplicates for primary hepatocytes and primary trophoblasts, respectively; **p < 0.01; ***p < 0.001.
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the difference between maternal and fetal apoE serum levels was less pronounced (20% increase) as compared to 
apoA1 (600% increase).
Discussion
In the present work, we determined for the first time the magnitude as well as the directionality of placental 
apoA1 and apoE secretion in two highly physiological human placenta models. We found that human term pla-
centa is able to secrete apoA1 and apoE to both the maternal and the fetal side. While apoA1 secretion in the 
human placenta perfusion model was predominantly orientated towards the maternal side, the Transwell system 
with primary trophoblast cells suggested higher apoA1 release towards the fetal side. For apoE, however, the 
secretion pattern consistently showed a predominant maternal orientation in both placenta models. Increased 
apoA1 and apoE concentrations at the maternal compartment were also found when corresponding maternal 
and fetal serum samples were analyzed. The magnitude of placental apo release was assessed by comparing the 
apo secretion capacities of human primary trophoblasts with human primary hepatocytes. We demonstrated that 
primary trophoblasts secrete comparable or even higher amounts of apoA1 and apoE than primary hepatocytes.
In order to validate the placenta perfusion system and to guarantee the reproducibility of the experiments, 
several parameters (e.g. pH, oxygen, carbon dioxide, glucose, lactate) were analyzed in the perfusates. Consistent 
with previous reports33,34, only perfusions with a leak of maximum 10% of the initial volume of fetal medium were 
included in this study. The measured parameters confirmed the reliability and reproducibility of the perfusions. 
Indeed, throughout all perfusion experiments, pH in the maternal and fetal perfusate were within the physio-
logical range of 7.3 to 7.4 and remained unchanged. The consumption of oxygen and glucose as well as lactate 
production, indicators of the metabolic condition of the perfused tissue, are also in line with previous reports34–36. 
Clearance of antipyrine and creatinine, molecules that passively pass membranes, are commonly used to provide 
reliable information on the overlap of the maternal and fetal circuits. In the present study, antipyrine and creati-
nine clearance are in accordance with published results of other laboratories37.
Using this validated ex vivo system, we aimed to determine the role of the placenta in the secretion of antiath-
erogenic lipoproteins. Pregnancy is characterized by important physiological changes in the maternal organism 
resulting in hyperlipidemia30, exposing the fetus to increased amounts of lipids. It has been reported that uptake 
of cholesterol by trophoblasts occurs via interaction of HDL and LDL/VLDL with lipoprotein receptors present 
at the apical trophoblast plasma membrane5. However, the route by which cholesterol exits the basal trophoblast 
membrane remains only poorly characterized. It has been demonstrated that cholesterol exits the trophoblast 
by secretion in newly formed lipoproteins or by efflux to acceptor molecules3,38,39. Studies reported that human 
term placental biopsies secrete apoB100-containing lipoproteins27, and that the choriocarcinoma cell line BeWo 
is able to release apoB40. To the best of our knowledge, only two reports have demonstrated secretion of apoA1 
and apoE by the human placenta28,29. The results of our ex vivo studies indicate that human term placenta secretes 
apoA1 and apoE to both the maternal and the fetal side. The release of apoA1 and apoE by the human term 
placenta, however, is predominantly directed towards the mother. In the present study both the secretion and 
the remaining stores of apoA1 and apoE in the placenta declined throughout the perfusion period. However, 
important differences were detected between the secretion patterns into the maternal and the fetal side. Indeed, 
the secretion of apoA1 and apoE to the maternal compartment seemed to be dependent on the placental stores. 
This was concluded from the finding that the apo fraction released towards the maternal side correlated well 
with the remaining apo concentration in the placental tissue. In contrast, when relating the apo secretion to the 
remaining placental tissue content at the fetal compartment, the secreted fraction of apoA1 and apoE was at the 
beginning approximately three fold higher than at the end of the perfusion. Taken together, these data suggest 
that with decreasing placental apoA1 and apoE stores, the “priority” of the apoA1 and apoE release by the pla-
centa is directed towards the mother.
To reinforce our ex vivo and in vitro data and relate them to the physiological context in the blood, we meas-
ured the levels of apoA1 and apoE in corresponding maternal and fetal serum samples obtained from healthy 
Figure 5. Quantification of apoA1 (A) and apoE (B) concentrations by ELISA in corresponding maternal 
and fetal serum samples collected immediately before (maternal) and within maximally one hour after 
delivery(fetal) by elective Cesarean section. Samples were obtained from healthy term pregnancies. Results 
represent mean ± SEM of 40 patients measured in duplicates; p < 0.0001.
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pregnancies. ApoA1 concentrations were significantly (600%) higher in maternal as compared to fetal serum 
samples. A similar and significant, but markedly less pronounced gradient (20%) was found for apoE. These find-
ings are in line with previous findings from Mistry et al. showing higher concentrations of apoA1 and apoE in the 
maternal as compared to the fetal plasma41. Interestingly, the dimension of the apo gradients between maternal 
and fetal serum samples measured in our cohort corresponds well with the results of the placenta perfusion stud-
ies. Thus, when calculating the ratio between maternal and fetal release in the placenta perfusion experiments, 
a much higher predominance for the maternal side was found for apoA1. Taken together these data suggest that 
the placenta plays a major role in regulating the apolipoprotein levels of the pregnant mother and the fetus. The 
findings of the present study are also consistent with the hypothesis that increased levels of antiatherogenic apoA1 
and apoE in the maternal blood may protect the mother from health complications arising from high lipid levels 
during pregnancy.
The physiological implications of the predominant maternally orientated secretion pattern found in the pres-
ent study are still unclear. However, previous studies showed that ABCA1, the molecular partner interacting with 
apoA1 to mediate cholesterol transport, is abundantly expressed at the maternal side in term placenta20,42. Thus, 
ABCA1-mediated cholesterol efflux may be supported in situ by placental release of apoA1. Moreover, it is tempt-
ing to speculate that the placenta contributes to the regulation of the mother’s lipid profile during pregnancy by 
secreting antiatherogenic apos. During pregnancy an increase of maternal lipid levels including triglycerides and 
total cholesterol has been reported15,43 and was associated with serious consequences for both the mother and the 
child, such as pregnancy-induced hypertension44,45, preeclampsia16,46 and preterm birth47,48.
To provide additional evidence for the apical or basal secretion of apos and to determine the cellular origin of 
apo release, primary trophoblasts growing on Transwell permeable filter support were used. This in vitro model 
has been previously used to study trophoblast transport from the apical (maternal) to the basal (fetal) side49,50. 
Using this system, we confirmed that cultured trophoblasts secrete apoE predominantly to the apical compart-
ment. Secretion to the basal side was detectable, but approximately four times lower. The remarkably higher secre-
tion of apoA1 to the maternal side found in the placenta perfusion studies, could, however, not be confirmed by 
the primary trophoblast experiments. This may be associated with the fact that apical apoA1 secretion decreased 
over time in culture, and was already negligible when a tight monolayer was formed. The constant decline in 
apoA1 secretion in trophoblasts may be associated with the continuous exposure of these cells to high (25 mM) 
glucose levels in the culture medium. A high glucose concentration in the medium is a technical prerequisite 
for proper adhesion and growth of primary trophoblast cells, but was also shown to inhibit apoA1 synthesis in 
epithelial cell types such as HepG2 cells51. In contrast, apoE secretion seems to be not majorly affected by high 
glucose levels as demonstrated in rats fed by a high glucose diet52. Interestingly, the basal secretion of apoA1 was 
maintained during the monolayer formation. This phenomenon could be related to the technical setup of the 
Transwell system: the apical surface of the monolayer is in direct and constant contact with high glucose con-
taining medium while at the basal side this condition is to a certain degree attenuated by the presence of a PET 
membrane coated with Matrigel.
On the other side, it is also possible that specific components present in the blood are needed for continuous 
secretion of apoA1, which were lacking in our cell culture system. This has been shown for apoB secretion which 
increased at the apical side only after treatment with estrogen53. Additionally, it has been demonstrated that 
the mRNA expression level of apoA1 was induced in response to glucocorticoids and insulin in primary hepat-
ocyte cells54. However, there are also indications that the stimulating effects of certain hormones (e.g. growth 
hormone, cortisol or thyroxine), which can affect metabolism and release of apos (e.g. apoB48 and apoB100), 
depend on whether they act on intact organs or isolated cells55. Moreover, the fact that our experiments were 
performed in the absence of cholesterol, could be a factor influencing the release and directionality of apos. In 
this context it has been previously shown that the cellular lipid content influences the synthesis and secretion of 
apoA16,56 and plasma HDL can affect the stability and secretion of apoA157–59. Thus future experiments in polar-
ized cell and perfusion models are warranted to investigate the contribution of cholesterol in affecting apo release 
and stabilization.
An alternative explanation for the discrepancy between the apoA1 results of the perfusion and the trophoblast 
Transwell model is that the latter lacks the contributions from stroma and endothelium. The perfused cotyledon 
comprises different cell populations like stroma and endothelium which may play a role in the secretion of apoA1. 
Although studies on the role of placental endothelial and stromal cells in apo homeostasis during pregnancy 
are scarce, synthesis of apoA1 and apoB by rabbit and bovine endothelium have been reported60,61. Similarly, 
the placental stroma tissue is often neglected in transport studies. Since the Glut4 transporter was unexpect-
edly shown to be expressed in villous stromal cells62, it became clear that the understanding of materno-fetal 
nutrient transport and related secretion processes becomes more complex. Hence in future work, it is impor-
tant to take the endothelial and stromal cells into consideration. In this context, the future establishment of a 
syncytium-endothelium co-culture model with primary cells could be beneficial for further clarification of apo 
homeostasis during pregnancy.
The fact the placenta secretes a considerable amount of apoA1 and apoE preferentially to the maternal side, 
prompted us to further investigate the physiological effects and consequences of this directional release. As 
apoA1 is an important acceptor protein for cholesterol and plays a crucial role in reverse cholesterol transport, 
we hypothesized that cholesterol efflux from term placenta occurs predominantly to the mother. Consistently, 
cholesterol efflux experiments performed in primary trophoblasts grown to confluent monolayers showed a sig-
nificantly higher cholesterol transport to the apical (maternal) as compared to the basal (fetal) side, independent 
of the addition of exogenous apoA1. These results are of physiological importance since cholesterol accumula-
tion in the placenta is considered as one of the major causes for pregnancy complications and diseases for the 
fetus63,64. Of note, the current experiments were performed exclusively on term placenta, when the fetus is rather 
independent from the maternal cholesterol supply. These observations suggest that at term the placenta may exert 
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a protective role both for the mother and the fetus by secreting anti-atherogenic apos. The latter have not only 
beneficial effects for the mother’s lipid homeostasis, thereby decreasing her risk to develop gestational complica-
tions (e.g. preeclampsia), but may also protect the fetus, through increasing cholesterol efflux to the maternal side.
The findings reported in the current study suggest that the placenta is an additional important organ capable 
of producing high levels of apos, especially apoA1 and apoE. Indeed, we found that apoA1 and apoE secretion by 
primary trophoblasts was equal or even higher than that observed from primary hepatocytes. Primary hepato-
cytes are known to secrete high amounts of apos31,32,65 and thus served as a well-accepted model of epithelial cells 
which have a proven role in regulating lipid homeostasis. The high amounts of apoA1 and apoE secreted by pla-
cental trophoblast cells in comparison with hepatocytes argues for a considerable contribution of the placenta in 
mediating during pregnancy the well documented anti-atherogenic effects of apoA1 and apoE22,24,66. These find-
ings further highlight a yet underestimated physiological role of the placenta, as currently only the liver and the 
intestine are considered as the predominant sources of apo secretion with major impact on lipid homeostasis31,32.
In summary, our results provide evidence for apical and basal secretion of two antiatherogenic apos: apoA1 
and apoE. Interestingly, the secretion of these two apos occurs predominantly to the apical (maternal) side which 
is in agreement with higher serum concentrations of both apos measured in the mother. Additionally, the com-
parison between hepatocytes and primary trophoblasts in culture confirmed that placental trophoblast cells 
secrete similar or even higher amounts of apoA1 and apoE than hepatocytes. Taken together, these data imply 
that in term pregnancies the predominantly apical release of apoA1 and apoE is relevant for the regulation of 
maternal cholesterol homeostasis.
Materials and Methods
Placenta collection. Human placental tissues were collected from the Division of Obstetrics and 
Gynecology, Lindenhofgruppe Bern, Switzerland, under approval by the ethical commission of the Canton of 
Bern (approval No Basec. 2016-00250). Written informed consent was obtained from all participants. Placentas 
were collected from uncomplicated pregnancies following elective cesarean section beyond 37 weeks of gestation 
without prior labour upon patients request or due to breech presentation. Table 2 shows a summary of the subject 
characteristics. All experiments were carried out in accordance with the relevant guidelines and regulations.
Placenta perfusion. For ex vivo studies, the single cotyledon placenta perfusion system was used as 
described by Schneider et al.67. Briefly, a fetal artery and vein on the chorionic plate were cannulated to set up a 
vascular circuit. Perfusion was started using Dulbecco’s modified Eagle medium (DMEM) and Earle’s balanced 
salt solution (EBSS) containing 2 g/L of glucose (Sigma, USA), 10 g/L Dextran FP40 (Serva, Germany) and 40 g/L 
bovine serum albumin (BSA, Sigma, USA). After confirmation of circulatory integrity, the cotyledon and portion 
of its surrounding placental tissue were transferred to a temperature-controlled (37 °C) chamber, where perfusion 
of the fetal circulation was continued as an open system at a flow rate of 15 mL/hour/cannula. The cylinder gas 
composition for the two circulations was 19% O2/5% CO2/76% N2 at the maternal and 5% CO2/95% N2 at the 
fetal side, respectively.
The original method of Schneider et al.67 had been modified by Soydemir et al.68, who instead of three to five 
cannulae used 22 cannulae for the maternal circuit. The cannulae were inserted at alternating depths of 1 and 
2 cm into the intervillous space. This modification allowed a better distribution of maternal perfusate inside the 
intervillous space and improved oxygenation of the trophoblast was reflected by the secreted cytokine profile69. 
For the present study depending on the cotyledon size 5 to 25 cannulae were inserted into the intervillous space 
to establish the maternal circulation. Maternal flow rate was initiated at 30 mL/hour/cannula as an open system.
The maternal and fetal artery pressure was monitored by a Millar instrument (Millar instruments, USA). The 
placental cotyledon circulations that leaked secondary to lack of vascular integrity or that did not achieve a stable 
pressure were excluded. After an initial 30 minutes washing phase, maternal and fetal venous perfusate samples 
were taken at 15, 30, 60, 120, 150, 180, 210 and 240 minutes (n = 4). Samples were collected in triplicate and 
centrifuged at 1100 g for 10 min at 4 °C to remove potentially eluted residual blood. Maternal and fetal perfusate 
samples were stored at −80 °C for subsequent analysis of apoA and apoE as described below.
Several parameters including the volume of the fetal perfusate, pH, oxygen consumption, glucose consumption, 
lactate production, antipyrine and creatinine transfer34 were evaluated in order to validate the perfusion system 
(Table 1). The antipyrine and creatinine concentrations in the placenta perfusion medium were 80 and 150 µg/mL, 
respectively. The formulas used for the calculation of these parameters are shown in Supplemental Table S1.
Clinical data
Mother
Blood pressure 
(mmHg)
Age 
(years)
Weight at 
birth (kg)
Height 
(cm)
BMI at birth 
(kg/m2)
Gestational 
age (weeks) Smoker Systolic Diastolic
34.4 ± 1.1 78.53 ± 4.9 167.1 ± 2.2 27.8 ± 1.2 37.73 ± 0.3 0/12 118.1 ± 3.6 72.4 ± 2.8
Placenta Newborn
Weight (g) Umbilical cord length (cm) Gender Weight (g)
618.9 ± 26.6 15.80 ± 1.9 9♂, 6♀ 3051 ± 128.1
Table 2. Clinical parameters of maternal, placental and fetal subjects (n = 15).
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Measurement of antipyrine and creatinine by capillary electrophoresis. Antipyrine and creatinine 
in the perfusate were monitored with a laboratory developed method based on micellar electrokinetic capillary 
chromatography (MECC). The assay comprises protein precipitation with trichloroacetic acid (TCA), hydrody-
namic injection of alkalinized sample and analysis at pH 9.3 in a phosphate/tetraborate MECC buffer with 50 mM 
SDS and 2% methanol. The buffer system is similar to that used previously for drug monitoring of antipyrine in 
plasma70. Calibrators, controls and blank sample were prepared with perfusion medium that contained 2.5 units/
mL liquemine (sodium heparin) and all reagents used were of analytical grade. 100 µL of perfusate, 20 µL of water, 
20 µL of internal standard solution (400 µg/mL caffeine, solution stored at −20 °C) and 40 µL of 0.5 M TCA solu-
tion were pipetted into a 0.5 mL Eppendorf vial, vortexed for 30 s and centrifuged at 13000 rpm for 5 min. 120 µL 
of the supernatant was transferred into a 0.5 mL plastic tube (Semadeni, Ostermundigen, Switzerland) and alka-
linized with 20 µL of 0.5 M NaOH. A P/ACE MDQ instrument (Beckman Coulter, Fullerton, CA, USA) equipped 
with a 50 µm I.D. fused-silica capillary (Polymicro Technologies, Phoenix, AZ, USA) of 60 cm total length (effec-
tive length 50 cm) was used. Samples were injected hydrodynamically via applying 1 psi (1 psi = 6894.8 Pa) for 
6 s. A voltage of 21 kV (normal polarity) was applied. The current was about 28 µA. Sample storage and capil-
lary cartridge temperatures were set to 20 and 22 °C, respectively, and analyte detection was effected at 200 nm 
(PDA detector). Creatinine, caffeine (internal standard) and antipyrine were detected after 5.6, 7.9 and 10.1 min, 
respectively. Quantification was based on seven-level internal calibration (antipyrine: 1–100 µg/mL; creatinine: 
2–200 µg/mL) and the lowest calibrators were used as quantification limits. Interday precision was <5.0% for all 
compounds.
Primary trophoblast isolation and characterization. For in vitro studies, we isolated villous troph-
oblasts from healthy human term placentas by enzymatic digestion and gravitational separation as previously 
described by Nikitina et al.71 with minor modifications. Briefly, villi-rich tissues were digested four times with 
0.25% trypsin (Sigma, USA) and 300 IU/ml Deoxyribonuclease I (Sigma, USA), and then subjected to Percoll® 
(Sigma, USA) density gradient centrifugation to isolate villous CTB. In order to assure the purity of the cells, 
flow cytometry analysis was performed by using the trophoblast-specific epithelial cell marker cytokeratin 772 
(anti-cytokeratin 7, Dako, Switzerland). Vimentin (anti-vimentin, Sigma, USA), which is only expressed in 
potentially contaminating cells (e.g. mesenchymal cells, fibroblasts, smooth muscle cells, stromal cells)73 served 
as a negative marker.
Primary trophoblast cell culture. Conventional culture plates. Isolated human trophoblast cells were 
cultured in Dulbecco’s modified Eagle’s medium containing 4.5 g/l glucose (DMEM-HG, Gibco, UK) supple-
mented with 10% fetal bovine serum (FBS, Seraglob, Switzerland) and antibiotic-antimycotic (Gibco, USA) in a 
humidified incubator under a 5% CO2 atmosphere at 37 °C. Cells were seeded at a density of 0.5 × 106 cells/cm2 
in costar CellBIND– 24 well plates (Corning, USA). The morphology of the cells was monitored with a Leica 
DMi1 microscope (Leica, Germany) and the medium was collected daily for 3 days to measure apo release by 
enzyme-linked immunosorbent assay (ELISA; see below).
Transwell experiments with primary trophoblasts. To determine the directionality of apoA1 and apoE release, we 
used trophoblast confluent monolayer grown on Transwell inserts (Falcon, USA) composed of apical (maternal) 
and basal (fetal) compartments. The trophoblasts were seeded at a density of 1 × 106 cells/cm2 on 6 well or 12 well 
Transwell inserts with 0.4 μm pore polyester membrane which were coated with Matrigel (BD Biosciences, USA) 
at a concentration of 25 µg/cm2 prior to the experiment. The trophoblast monolayer formation was evaluated by 
the tightness and barrier integrity as described74. In brief, trans-epithelial electrical resistance (TEER) was meas-
ured every day for 5 days using Millicell ERS-2 Volt-Ohm Meter (Millipore, USA) as described74. The TEER value 
was determined on the Matrigel-coated inserts in the presence or absence of trophoblast cells. Additionally, the 
vectorial permeability properties were evaluated by the diffusion of fluorescent dye Lucifer Yellow (Sigma, USA) 
as described in74. In the applied Transwell cell model, the human villous trophoblast barrier represents a contin-
uous STB layer together with underlying CTB, proven by electron microscopy, mRNA and protein expressions of 
specific markers74. Stacked multinucleated and mononucleated cells were observed using electron microscopy; 
staining with the CTB marker E-cadherin revealed predominant expression in the mononuclear cells.
After confirmation of monolayer formation medium samples were collected for the measurement of apoA1 
and apoE secretion from the apical and basal compartments on day 1, 3 and 5 of culture.
Primary hepatocyte isolation and cultivation. Normal human liver tissue was taken from the periph-
ery of liver specimens from patients undergoing surgical resection for colorectal metastases. Informed consent 
of the patients was obtained in accordance with institutional guidelines and the local ethics committee. The iso-
lation procedure is described in detail by Portmann et al.75 in the Supplementary Information. Briefly, cells were 
isolated using a two-step enzymatic perfusion protocol. The viability of the isolated hepatocytes was determined 
by trypan blue exclusion, and only preparations of over 90% viability were used. The hepatocytes were seeded 
at a density of 75’000 cells/cm2 onto rat tail collagen coated 6 well tissue culture plastics in DMEM containing 
10% fetal bovine serum (FBS) (Life Technologies, Switzerland), left to attach for 1 to 2 hours, and then washed 
twice with phosphate-buffered saline (PBS) (Life Technologies, Switzerland) to remove unattached cells. The 
hepatocytes were cultured in arginine-free medium made from a powdered base according to the formula-
tion of Williams-E, supplemented with insulin (0.015 IU/mL, NovaRapid, Novo Nordisk), hydrocortisone (5 
μmol/L, Sigma, Switzerland), penicillin, streptomycin, glutamine (100 IU/mL, 100 μg/mL, 2 mmol/L, GPS, Life 
Technologies, Switzerland), and ornithine (0.4 mmol/L, Sigma, Switzerland). During 3 days in culture, medium 
was collected daily and analyzed for apoA and apoE secretion.
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The quality and reproducibility of hepatocytes produced using this method is described in Bhogal et al.76. 
Herein the authors refer to “normal” liver when the hepatocytes are isolated from resections which is the same 
source we used for the current experiments.
Collection of blood samples. Blood from healthy pregnant women was collected from the maternal vein 
before delivery (n = 40) and from the umbilical cord vein immediately after delivery of the placenta (n = 40). 
Blood samples were collected in S-Monovette serum tubes (Sarstedt AG, Germany) and processed within 1 h. 
Samples were allowed to clot at RT and then serum was obtained after centrifugation at 2000 g for 10 mins at 4 °C. 
Serum samples were aliquoted and stored at −20 °C until further use as described in77,78.
ELISA analysis of apoA1 and apoE secretion. ApoA1 and apoE were measured by a commercially 
available ELISA kit (Mabtech AB, Germany) according to the manufacturer’s instructions. In brief, the range 
of the standard curve was from 0.1 to 1000 ng/ml and from 0.02 to 100 ng/ml for apoA1 and apoE, respectively. 
The perfusion samples of the maternal side were diluted 1/300 and 1/5 for apoA1 and apoE, respectively, using 
Dulbecco’s phosphate buffered saline (DPBS, Sigma, USA) with 0.05% Tween-20 (Sigma, USA) containing 0.1% 
bovine serum albumin (BSA, Sigma, USA). The serum samples were diluted 1/200’000 for apoA1 and 1/20’000 
for apoE in Apo ELISA buffer as suggested in the manufacturer’s instructions. 100 or 200 μl of standard and 
diluted samples were dispensed into wells. After two-hour incubation, the samples were aspirated and the wells 
were washed five times with DPBS containing 0.05% Tween-20. The antibody-HRP conjugate was then applied 
for one hour. After five consecutive washing steps, the substrate solution p-nitrophenyl-phosphate (pNPP, Sigma, 
USA) was added and left for one hour until completion of the chemical reaction. The absorbance was measured 
at 405 nm using a Vmax4.8 microplate reader (Molecular Devices, USA). The concentrations were calculated by 
subtracting the mean absorbance value of the blank from the standard and sample values prior to creating the 
standard curve. The concentrations of apoA1 and apoE secretion in samples were then interpolated from the 
slope of the respective standard curve and the obtained values were multiplied with the dilution factor. Finally, 
the concentrations of apo release were normalized to the weight of the cotyledon (perfusion samples) or to the 
protein concentration (tissue and cell samples). Placental tissue lysates before and after the perfusion were pre-
pared using hypotonic buffer supplemented with protease inhibitors. Protein concentrations in placental tissues 
and cells were measured using Pierce BCA protein assay kit (Thermo Scientific, USA).
Statistics. All statistical analyses were performed with GraphPad Prism software (GraphPad software, USA). 
Data are shown as mean ± SEM of at least four independent experiments performed in triplicates. The changes 
in apoA-1 and apoE secretion levels in ex-vivo and in vitro models were tested for significance by using one-way 
ANOVA followed by Tukey’s post-test. The apo contents in placental tissues before and after perfusion as well as 
the maternal and fetal serum samples were tested by using paired t-test. The alpha level of all mentioned tests was 
0.05. The level of statistical significance was set at p < 0.05.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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